Brief: Suven Life Sciences secures product patent in New Zealand
March 28 (Reuters) - Suven Life Sciences Ltd SUVP.NS
* Says Suven Life Sciences secures a product patent in New
Zealand
* Says patent is valid through 2033
* Grant of 1 product patent for new chemical entities for
the treatment of disorders associated with neurodegenerative
diseases
Source text for Eikon: ID:nBSE77Qmd2
Further company coverage: SUVP.NS
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Suven Life Sciences
See all newsBrief: Suven Life Sciences Completes Patient Enrollment In Global Phase-3 Masupirdine Study
India's Suven Life Sciences gains after Masupirdine Phase-3 study completes patient enrollment
Brief: Suven Life Sciences Completes Phase-1 Study Of SUVN-I6107, Advances To Phase-2
Brief: Suven Life Sciences Reports Positive DSMB Safety Review For Phase-3 Masupirdine Study
Brief: Suven Life Sciences Records 100% Patient Enrolment Milestone In Phase-2B Clinical Trial Of Ropanicant